Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia

Trial Profile

An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mirogabalin (Primary)
  • Indications Fibromyalgia; Pain
  • Focus Adverse reactions; Registrational
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 31 Aug 2017 According to a Daiichi Sankyo media release, the results from the global clinical development program consisting of several phase 3 clinical trials, including NEUCOURSE, REDUCER and ALDAY, will serve as the basis for potential regulatory submissions in various countries.
    • 01 Jul 2017 This trial was completed in Slovenia (end date: 2017-04-19), according to European Clinical Trials Database.
    • 30 Jun 2017 Status changed from active, no longer recruiting to completed, according to a Daiichi Sankyo media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top